本文選題：企業(yè)發(fā)展能力 + 醫(yī)藥制造企業(yè)　； 參考：《北京交通大學(xué)》2017年碩士論文

【摘要】：隨著全球一體化進(jìn)程的不斷加快和市場(chǎng)經(jīng)濟(jì)的不斷發(fā)展,企業(yè)之間的競(jìng)爭(zhēng)也不斷加劇,評(píng)價(jià)和分析企業(yè)發(fā)展能力的重要性日益凸顯。本文基于對(duì)企業(yè)發(fā)展能力本質(zhì)的探討,選擇了具有代表性的醫(yī)藥制造行業(yè)展開研究。通過分析醫(yī)藥制造行業(yè)的發(fā)展現(xiàn)狀和特點(diǎn),總結(jié)得出醫(yī)藥制造企業(yè)發(fā)展能力的影響因素,構(gòu)建了醫(yī)藥制造企業(yè)發(fā)展能力評(píng)價(jià)指標(biāo)體系。運(yùn)用主成分分析法,利用醫(yī)藥制造行業(yè)上市公司2013-2015年數(shù)據(jù),構(gòu)建了醫(yī)藥制造企業(yè)發(fā)展能力評(píng)價(jià)模型,計(jì)算得出整個(gè)行業(yè)的得分并進(jìn)行簡(jiǎn)要分析,并利用行業(yè)數(shù)據(jù)進(jìn)行了有效性檢驗(yàn)。最后,選取了兩家醫(yī)藥制造行業(yè)上市公司即雙鷺?biāo)帢I(yè)和華北制藥作為案例,應(yīng)用該模型對(duì)兩家企業(yè)的發(fā)展能力進(jìn)行對(duì)比評(píng)價(jià)與分析,發(fā)掘醫(yī)藥制造企業(yè)發(fā)展能力存在的問題并提出建議。本文研究思路與已有研究的區(qū)別在于:(1)已有研究很少同時(shí)對(duì)企業(yè)發(fā)展能力與企業(yè)成長(zhǎng)性、企業(yè)能力、企業(yè)競(jìng)爭(zhēng)力等相關(guān)概念進(jìn)行闡釋和區(qū)分,本文基于對(duì)企業(yè)發(fā)展能力本質(zhì)的探討和相關(guān)理論的總結(jié)梳理,界定了企業(yè)發(fā)展能力和其它相關(guān)的概念,闡述了企業(yè)發(fā)展能力與其它概念的區(qū)別和聯(lián)系。(2)已有研究多只進(jìn)行企業(yè)發(fā)展能力模型構(gòu)建,并簡(jiǎn)單地進(jìn)行行業(yè)描述性分析,無法深入體現(xiàn)模型的應(yīng)用價(jià)值。本文在構(gòu)建醫(yī)藥制造企業(yè)發(fā)展能力評(píng)價(jià)模型并利用行業(yè)數(shù)據(jù)進(jìn)行有效性檢驗(yàn)的基礎(chǔ)上,將模型應(yīng)用于雙鷺?biāo)帢I(yè)和華北制藥兩個(gè)案例。本文有以下研究發(fā)現(xiàn):(1)基于企業(yè)成長(zhǎng)理論和企業(yè)能力理論,本文認(rèn)為企業(yè)發(fā)展能力是能力視角下的企業(yè)成長(zhǎng)性(尤其是內(nèi)生成長(zhǎng)性)的體現(xiàn),是指企業(yè)通過投入和運(yùn)用資源形成的內(nèi)部潛力和外部擴(kuò)張力。(2)醫(yī)藥制造企業(yè)發(fā)展能力影響因素包括外部因素(經(jīng)濟(jì)環(huán)境、行業(yè)政策和社會(huì)健康問題)以及內(nèi)部因素(人力資源、研發(fā)水平、現(xiàn)有經(jīng)營(yíng)管理水平、未來持續(xù)經(jīng)營(yíng)可能和企業(yè)規(guī)模),由此構(gòu)建的醫(yī)藥制造企業(yè)發(fā)展能力評(píng)價(jià)指標(biāo)體系和模型由學(xué)習(xí)創(chuàng)新能力、經(jīng)營(yíng)拓展能力、盈利能力、營(yíng)運(yùn)能力、償債能力、持續(xù)經(jīng)營(yíng)能力和規(guī)模擴(kuò)張能力等七個(gè)維度、十五個(gè)指標(biāo)構(gòu)成。(3)2013-2015年,醫(yī)藥制造企業(yè)發(fā)展能力得分主要分布在-2～2的區(qū)間范圍內(nèi),且整體分布較為均勻。其中,42.19%的醫(yī)藥制造企業(yè)發(fā)展能力表現(xiàn)良好或較好。總體來看,醫(yī)藥制造企業(yè)發(fā)展能力仍然存在較大的提升空間。(4)醫(yī)藥制造企業(yè)發(fā)展能力存在著產(chǎn)品同質(zhì)化、技術(shù)門檻低及結(jié)構(gòu)單一,經(jīng)營(yíng)管理水平有待提高,人才儲(chǔ)備和研發(fā)投入不足等短板,為此企業(yè)需要注重優(yōu)化產(chǎn)品結(jié)構(gòu)和產(chǎn)業(yè)布局,調(diào)整資本結(jié)構(gòu)和加強(qiáng)財(cái)務(wù)管理以及提升人力資源投資水平和研發(fā)水平。本文主要?jiǎng)?chuàng)新在于:(1)基于相關(guān)研究現(xiàn)狀和理論基礎(chǔ)的梳理,本文對(duì)企業(yè)發(fā)展能力的概念進(jìn)行了界定,對(duì)理論體系進(jìn)行了整合與充實(shí),具有一定的理論創(chuàng)新性。(2)基于醫(yī)藥制造行業(yè)發(fā)展現(xiàn)狀和特點(diǎn)總結(jié)得出醫(yī)藥制造企業(yè)發(fā)展能力影響因素,本文由此構(gòu)建了醫(yī)藥制造企業(yè)發(fā)展能力評(píng)價(jià)指標(biāo)體系和模型。(3)通過對(duì)兩家具有代表性的醫(yī)藥制造企業(yè)發(fā)展能力各維度進(jìn)行剖析,本文發(fā)掘出醫(yī)藥制造企業(yè)發(fā)展能力存在的問題并提出建議。
[Abstract]:With the continuous acceleration of the global integration process and the continuous development of the market economy, the competition between enterprises is increasing. The importance of evaluating and analyzing the development ability of enterprises is becoming more and more important. Based on the discussion of the essence of the ability of enterprise development, this paper chooses a representative pharmaceutical manufacturing industry to carry out research. The current situation and characteristics of the development of the industry, summed up the influencing factors of the development ability of pharmaceutical manufacturing enterprises, and constructed the evaluation index system of the development ability of pharmaceutical manufacturing enterprises. By using the principal component analysis method and using the data of 2013-2015 years of the listed companies of pharmaceutical manufacturing industry, the evaluation model of the development ability of pharmaceutical manufacturing enterprises was constructed, and the whole calculation was calculated. The score of the industry is analyzed briefly, and the validity of the industry data is tested. Finally, two pharmaceutical industry listed companies, double Heron pharmaceutical and North China pharmaceutical, are selected as a case. The model is used to compare and analyze the development ability of the two enterprises, and to explore the existence of the development ability of the pharmaceutical manufacturing enterprises. The differences between the research ideas and the existing research are as follows: (1) there are few existing studies explaining and distinguishing the related concepts of enterprise development ability and enterprise growth, enterprise ability and enterprise competitiveness. Based on the discussion of the essence of enterprise development ability and the summary of related theories, this paper defines the enterprises' development. Ability and other related concepts, and explain the difference and connection between the ability of enterprise development and other concepts. (2) many studies have been carried out to build the model of enterprise development ability, and simply carry out industry descriptive analysis, and can not reflect the application value of the model in depth. On the basis of the validity test of the industry data, the model is applied to two cases of double Heron pharmaceutical and North China Pharmaceutical. The following studies have found that: (1) based on the theory of enterprise growth and the theory of enterprise ability, this paper thinks that the enterprise development ability is the embodiment of enterprise growth (especially endogenous growth) from the perspective of ability, which refers to the enterprise (2) the factors affecting the development capacity of pharmaceutical manufacturing enterprises include external factors (economic environment, industry policy and social health problems) and internal factors (human resources, R & D level, current management level, future sustainable management and enterprise scale), which are constructed. The development capability evaluation index system and model of pharmaceutical manufacturing enterprises are composed of seven dimensions, including learning innovation ability, business development ability, profitability, operation ability, solvency, sustainable management ability and scale expansion ability. (3) 2013-2015 years, the development ability score of medical manufacturing enterprises is mainly distributed in the range of -2 to 2. Within the scope, the overall distribution is more uniform. Among them, 42.19% of the pharmaceutical manufacturing enterprises have good or better development ability. In general, the development ability of pharmaceutical manufacturing enterprises still has a greater promotion space. (4) the development ability of pharmaceutical manufacturing enterprises is homogenized, the technical threshold is low and the structure is single, and the management level needs to be raised. The enterprises need to pay attention to optimizing the structure of products and the layout of the industry, adjust the capital structure, strengthen the financial management and improve the level of human resources investment and research and development. The main innovation of this paper is: (1) this article is based on the present situation and theoretical basis of related research. The concept of force is defined and the theoretical system has been integrated and enriched. (2) based on the development status and characteristics of the pharmaceutical manufacturing industry, the factors affecting the development ability of pharmaceutical manufacturing enterprises are summarized. This paper constructs the evaluation index system and model of the development ability of pharmaceutical manufacturing enterprises. (3) through two This paper analyzes the dimensions of the development capability of the representative pharmaceutical manufacturing enterprises, and explores the problems existing in the development capability of pharmaceutical manufacturing enterprises and puts forward some suggestions.

【學(xué)位授予單位】：北京交通大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類號(hào)】：F426.72;F406.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張蕾;;醫(yī)藥類上市公司的成長(zhǎng)性研究[J];時(shí)代金融;2016年33期

2 陳紫晴;楊柳勇;;融資結(jié)構(gòu)、R&D投入與中小企業(yè)成長(zhǎng)性[J];財(cái)經(jīng)問題研究;2015年09期

3 羅琦;王悅歌;;真實(shí)盈余管理與權(quán)益資本成本——基于公司成長(zhǎng)性差異的分析[J];金融研究;2015年05期

4 司玉娟;;以S公司為例談平衡計(jì)分卡績(jī)效評(píng)價(jià)體系的構(gòu)建[J];商業(yè)會(huì)計(jì);2015年01期

5 宋獻(xiàn)中;吳一能;寧吉安;;貨幣政策、企業(yè)成長(zhǎng)性與資本結(jié)構(gòu)動(dòng)態(tài)調(diào)整[J];國(guó)際金融研究;2014年11期

6 張龍;陳丹鏑;陳迪;劉軍;;基于杜邦分析法的我國(guó)生物醫(yī)藥行業(yè)財(cái)務(wù)狀況分析[J];中國(guó)藥房;2014年21期

7 章立;朱海亮;;生物醫(yī)藥企業(yè)成長(zhǎng)性評(píng)價(jià)體系研究[J];中國(guó)新藥雜志;2014年06期

8 李敏娜;王鐵男;;董事網(wǎng)絡(luò)、高管薪酬激勵(lì)與公司成長(zhǎng)性[J];中國(guó)軟科學(xué);2014年04期

9 王佳麗;孫長(zhǎng)江;;醫(yī)藥制造業(yè)上市公司企業(yè)成長(zhǎng)性評(píng)價(jià)研究[J];商業(yè)會(huì)計(jì);2014年07期

10 張秀生;劉偉;;創(chuàng)業(yè)板上市企業(yè)成長(zhǎng)性影響因素研究[J];統(tǒng)計(jì)與決策;2013年15期

相關(guān)碩士學(xué)位論文 前1條

1 林嘉獻(xiàn);我國(guó)上市公司成長(zhǎng)性分類的實(shí)證研究[D];吉林大學(xué);2006年

，

本文編號(hào)：1803018